Haysaw, I agree on your assessment of Cortex management. PTN has been down to .10 recently, and I believe they are topping short-term at .34 due to the Bremelanotide buzz from the Men's Journal one page story. Hell, it might have been a paid advert?
But, any press is good press. So, if on a pullback, PTN gets cheaper than COR, I will probably do a partial swap. Anything beats sitting here in Cortex waiting for signs of life. MF4
Market Data 
Markets 
AI
